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Summary
Cancer is a genetic disease caused by the progressive accumu-
lation of mutations in critical genes that control cell growth
and differentiation. Completion of the Human Genome Project
promises to revolutionize the practice of Medicine, especially
Oncology care. The tremendous gains in the knowledge of the
structure and function of human genes will surely impact the
diagnosis, prognosis and treatment of cancer. Moreover, it will
lead to more effective cancer control through the use of genetics
to quantify individual cancer risks. This article reviews the
current status of genetic testing and counseling for cancer risk
assessment and will suggest a framework for integrating such
counseling into oncology practice.
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Introduction
Genetic counseling translates basic scientific knowledge
into a practical and understandable form of information
for the patient. The ethical, legal and psychosocial im-
plications of genetic testing for inherited cancer syn-
dromes are such that adequate counseling pre- and
post- genetic testing is mandatory. Many professional
groups including the American College of Medical
Genetics and the National Society of Genetic Counse-
lors, the American Society of Clinical Oncology and the
European Familial Breast Cancer Collaborative Group
have published policies and guidelines as well as a
curriculum of essential concepts in cancer genetics re-
quired of all health professionals [1-5]. These guidelines
emphasize the importance of counseling prior to genetic
testing for adult onset cancers. While genetic testing has
become standard of care for rare conditions such as
familial adenomatous polyposis and medullary thyroid
carcinoma, testing remains underutilized in oncology
practice.
With completion of the Human Genome project, the
medical community stands poised to take advantage of
the new knowledge. A number of susceptibility genes for
common cancers such as breast, ovary and colon have
been identified and individuals with family histories of
such cancers can have a more precise estimation of their
risk through the use of genetic testing (Table 1). This has
led to the development of programs offering genetic
counseling for cancer with the intent of incorporating
genetic testing in the clinical management of cancer
patients and their at risk relatives. The American Society
of Clinical Oncology encourages use of genetic testing
for cancer in the context of a comprehensive cancer risk
assessment [3]. Until we have a clear understanding of
the risks, benefits and limitations of genetic tests, it is
preferable that genetic testing be performed at centers
with access to the educational, counseling, research and
follow up resources currently available only at major
medical centers. Nonetheless, it is imperative that all
health care providers, in particular those in oncology
practice have a proper understanding of the issues sur-
rounding genetic testing and counseling. Oncologists
could play a pivotal role in cancer prevention through
their ability to access cancer patients and their at risk
family members. The responsibility to accurately assess
familial cancer risks, and counsel patients about the
appropriateness of more specialized genetic counseling
and testing should become an integral part of a compre-
hensive oncology practice. In North America, Oncologist
have been actively engaged in bringing cancer genetics
to the clinic; in Europe while there is increasing aware-
ness among Oncologists, genetic counseling is mainly
provided in the few specialized onco-genetics clinics
available in the different countries [2].
Breast cancer genetics
Breast cancer poses a major health problem for women
in most industrialized countries of the world. Epidemio-
logical studies have provided much information on im-
portant risk factors for the disease [6, 7]. These include
age, family or personal history of breast cancer, repro-
ductive history and exposures to specific carcinogens.
In a series of breast cancer patients presenting in an
oncology clinic, Lynch et al. documented a family his-
tory of breast cancer in 32% of 325 consecutive breast
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cancer patients seen in the clinic [8]. However, estimates
from population based studies suggest that only 5%-10%
of breast cancers are explained by germline mutations
in highly penetrant susceptibility genes such as BRCA1
and BRCA2 [9, 10]. These mutations are inherited in an
autosomal dominant fashion with varying penetrance
[11-13]. Young age at diagnosis (<45 years old), multiple
affected members in a family, bilateral disease and asso-
ciation with other cancers, particularly ovarian cancer
and sarcoma are features of inherited breast cancer that
can aid clinicians in recognizing individuals who may be
carriers of mutations in a breast cancer susceptibility
gene.
Breast cancer risk assessment
Data from different epidemiological studies have been
used to derive a woman's cumulative breast cancer risk.
Tabular risk data compiled by Claus et al. from the
Cancer and Steroid Hormone Study (CASH) are avail-
able and can be readily applied to clinical situations [6].
The CASH data takes into account age of onset of
affected relatives, which has been shown to be a strong
predictor of hereditary risk. The Gail model uses five
variables including: current age, age at first live birth,
age at menarche, number of first-degree relatives with
breast cancer and number of breast biopsies to calculate
risk ratios [14]. A modified Gail model is available for
clinical use and can be readily accessed through the US
National Cancer Institute website at http://cancernet.
nci.nih.gov/bcra_tool.html [15]. Unfortunately, the Gail
model may underestimate hereditary breast cancers be-
cause it does not consider paternal family history or the
presence of breast cancer in second-degree relatives, nor
does it take into account cases of ovarian cancer in the
family. The Claus model may be more applicable to
individuals with inherited breast cancer because it in-
corporates age of cancer in affected first and second
degree relatives. Both models remain clinically useful
tools despite their limitations. The modified Gail model
is widely used as a tool for risk assessment in the
National Surgical Adjuvant Breast and Bowel breast
cancer prevention trials [16]. For families with breast
cancer, Couch et al. [17], Parmigiani and Berry [18] as
well as Frank et al. [11] have published different models
for calculating the probability of finding an inherited
mutation in BRCA1 and BRCA2 genes. These models
are readily available and can aid clinicians and genetic
counselors in determining who is most likely to benefit
from genetic testing.
Breast cancer susceptibility genes
Although mutations in several genes confer increased
breast cancer risk, BRCA1, BRCA2 and TP53 genes
appear to be the most relevant in the clinic (Table 1). To
date, deleterious mutations in BRCA1 and BRCA2 ac-
count for the largest proportion of inherited breast
cancers. The proportion of inherited breast cancers due
to BRCA1 and BRCA2 range in estimate from 30%
in clinic based families to 84% in the Breast Cancer
Linkage Consortium [18-20]. TP53 and PTEN each
account for less than 1% of cases [21, 22]. Heterozygous
ATM mutation carriers have an increased risk of breast
cancer but the magnitude of risk is not quantified [23].
Other genetic conditions with associated breast cancer
risks include Muir Torre syndrome with MLH1 muta-
tions and Peutz Jeghers syndrome with LKB1/STK1
mutations (Table 1). One of the major limitations of
genetic testing in the clinical setting is that it now mostly
focuses on identifying mutations in BRCA1 or BRCA2
genes and may falsely reassure patients with mutations
in other cancer susceptibility genes.
BRCA1 gene
In 1990, investigations in families with a high incidence
of breast and/or ovarian cancers led to the localization
of a single autosomal dominant cancer susceptibility
gene called BRCA1 on chromosome 17q 12-21.1 [24].
The gene was cloned in 1994 and is now marketed as a
clinical test licensed by Myriad Genetics Laboratories
[11, 25]. When there are multiple breast cancers in a
family, the frequency of BRCA1 mutations ranges from
7% (families with only breast cancer) to 40% (families
with both breast and ovarian cancer) [17]. Even among
women with early onset of breast cancer, BRCA1 muta-
tion rates vary from only 3.3%—8%, despite the view that
early onset is the best predictor of BRCA1 mutations in
the absence of family cancer histories [19].
A recent report examined the contribution ofBRCAJ
and BRCA2 to inherited breast cancer when there were at
least four cases of breast cancer diagnosed under age 60
years within a family. These authors found that BRCA1
was associated with 52% of families and BRCA2 with
32% of families [20]. Neither gene was associated with
breast cancer in 16% of families, consistent with the
view that there may be at least one remaining unidenti-
fied breast cancer susceptibility gene. Moreover, when
both breast and ovarian cancer were present in families
from this set, the frequency of BRC'A 1 mutations rose to
81% and BRCA2 mutations fell to 14%. When both male
and female breast cancer were seen in these families, the
frequency of BRCA2 mutations rose to 76%. Interest-
ingly, families with more than five cases of female breast
cancer were less likely to have a mutation in either gene.
With more widespread testing in the high-risk clinics
and population based studies, there remains a signifi-
cant number of breast and/or ovarian cancer families
without identifiable mutations in BRCA1 or BRCA2.
Lately, a number of these families have been shown to
have large genomic rearrangements that were previously
missed by coding region sequence analyses [26, 27].
BRCAl is a large gene containing 5,592 nucleotides
spread out over approximately 100,000 bases of genomic
Table 1. Summary of selected inherited adult cancer syndromes.
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Syndrome Primary tumor Associated cancer or traits Chromosome
location
Cloned gene Proposed function of gene
product
Dominant syndromes:
Li-Fraumeni Sarcomas breast Brain tumors, leukemia, 17pl3.1
syndrome cancer lymphoma
Familial adenoma- Colorectal cancer Colorectal adenomas duo- 5q21
tous polyposis denal and gastric tumors
CHRPE, jaw osteomas and
desmoid tumors (Gardner Sy)
medulloblastoma (Turcot Sy)
TP53
A PC
Transcription factor; response
to DNA damage and stress,
apoptosis
Regulation of p-catemn,
microtubule binding
Hereditary
non-polyposis
colorectal cancer
Hereditary diffuse
gastric cancer
Neurofibromatosis
type 1
Neurofibromatosis
type 2
Wilm's tumor
Beckwith-Wiedman
syndrome
Colorectal cancer
Gastric cancer
Neurofibromas
Acoustic neuromas,
meningioma
Wilm's tumor
Wilm's tumor
Endometrial, ovarian,
hepatobiliary and urinary
tract cancer, glioblastoma
Lobular carcinoma,
? colorectal cancer
Neuroflbrosarcoma, A ML,
brain tumors
Ghomas, ependymomas
Wilm's anindia. genitourinary
abnormalities, mental retar-
dation
Organomelaly, hemihyper-
trophy, hepatoblastoma,
adrenocortcial cancer
2pl6, 3p21,
2q32. 7p22,
2pl6
16q21-22
17qll 2
22ql2.2
Ilpl3
11 pi 5
MSH2, MLHI.
PMS1, PMS2.
MSH6
CDH1
NF1
NF2
Links
membrane
WT1
KIP2p57
DNA mismatch repair
Transmembrane cell adhesion
molecule
GAP for p21 ra.v proteins;
microtubule binding
Proteins to cytoskeletons
Transcriptional repressor
Cell cycle regulator
Nevoid basal cell
carcinoma Sy
Hereditary breast
cancer 1
Hereditary breast
cancer 2
Basal cell skin
cancer
Breast cancer
Breast cancer
Jaw cysts, palmar andplantar
pits, medulloblastomas,
ovarian fibromas
Ovarian cancer
Ovarian cancer, male breast
cancer, pancreatic cancer,
other'
9q22.3
17q21
PTCH
BRCA1
17q21,13ql2 BRCA2
Transmembrane receptor for
hedgehog signaling molecule
In a complex with Rad51
protein, repair of double
stand breaks, transcription
factor
Directly interacts with Rad51
protein, repair of double
strand breaks
Von Hippel-Lindau
syndrome
Hereditary papil-
lary renal cancer
Familial melanoma
Multiple endocrine
neoplasia type 1
Multiple endocrine
neoplasia type 2
Hereditary multiple
exostoses (HME)
Cowden disease
Hereditary prostate
cancer
Palmoplantar,
keratoderma
Renal cancer
(clear cell)
Renal cancer
papillary type
Melanoma
Pancreatic islet cell
Medullary thyroid
cancer
Exostoses (cartilagi-
nous protuberances
on bones)
Breast cancer,
thyroid cancer
(follicular type)
Prostate cancer
Esophageal cancer
Pheochromocytomas retinal
angiomas, cerebellar capillary
hemangiomas
Other cancers
Pancreatic cancer, dysplastic
Nevi, atypical moles
Parathyroid hyperplasia,
pituitary adenomas
Type 2A pheochromato-
cytoma, parathyroid hyper-
plasia, type 2B pheochromo-
cytoma. mucosal hamartoma.
familial medullary thyroid
cancer
Chondrosarcoma
Intestinal hamartomas
polyps, skin lesions
Unknown
Leukoplakia
3p25
7q3l
9p21, 12ql3
I l q l 3
10qll .2
8q24.1,
11 pi 1 — 13.
19p
IOq23
Iq25
17q25
VHL
MeT
CDNK2A
(pl6), CDK4
MEN1
MEN2
EXT I, EXT2.
EXT3
PTEN.
MMAC1
Unknown
Unknown
Regulates transcriptional
elongation by RNA
polymerase 11
Transmembrane receptor for
hepatocyte growth factor
Inhibitor of CDK4 and
cychn-dependent kinases.
cyclin-dependent kinase
Regulation o(JUN-D
mediated transcription
Transmembrane receptor,
tyrosine kinase for glial
derived neurotropic growth
factor
Glycosyl transferases involved
in synthesis of heparan sulfate
Dual-specificity phosphatase
with similarity to tensin
Unknown
Unknown
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Table I Continued.
Syndrome
Recessive syndromes.
Ataxia
tclcangieclasia
Bloom's syndrome
Xeroderma
pigmenlosum
FanconTs anemia
Primary tumor
Lymphoma
Solid tumors
Skin cancer
AML
Associated cancer or traits
Cerebellar ataxia, immuno-
deficiency, breast cancer in
heterozygotes
Immunodeficiency, small
stature
Pigmentation abnormalities,
hypogonadsim
Pancytopenia, skeletal
abnormalities
Chromosome
location
Ilq22
15q26 1
Multiple
complentation
groups
9q22.3
16q24.3
others
Cloned gene
ATM ofp53
BLM
XPB. XPD,
XPA
FACC
FACC
FACA
Proposed function of gene
product
DNA repair, induction
Encodes DNA helicase,
member of Rec Q family
DNA repair, helicases
nucleotide excision repair
DNA repair
DNA repair
DNA repair
Abbreviations: CHRPE - congenital hypertrophy of the retinal pigment epithelium; AML - acute myelogenous leukemia; GAP - guanosine
triphosphatasc-activating protein, a negative regulator of the p2l ras guanine nucleotide-binding proteins, contigous gene disorder - alterations in several
distinct genes in a particular chromosomal region account for the phenotype seen in patients with the disorder; hedgehog - a secreted factor that regulates
cell fate determination via its binding to the PTCH protein
Adapted from Fearon ER. Human cancer syndromes: Clues to the origin and nature of cancer Science 1997; 278: 1043-50.
DNA [24]. The gene is composed of 24 coding exons
producing a protein of 1,863 amino acids. More than
700 mutations and sequence variations have been de-
tected so far and only a few are recurrent in unrelated
families [28]. Recurrent BRCA1 mutations have been
described in different European countries and in North
America but the two most common are 185delAG and
5382insC [28], BRCAl is a tumor suppressor gene
thought to function by altering the expression of other
genes and by participating in the cellular response to
DNA damage [29, 30].
viduals with early onset breast cancer (Table 2). However,
BRCAl mutations have been detected in both healthy
individuals and cancer patients with no significant family
histories of cancer. These cases may reflect paternal
inheritance of the mutation or low penetrance of the
alleles involved. Additionally, patients may not be aware
of their biological families'cancer histories, or may come
from small families with few at risk individuals. Nonethe-
less, testing for BRCA1/2 mutations should be offered
only when indicated by a comprehensive risk assessment,
and in the context of long-term clinical follow-up.
BRCA2
The second breast cancer susceptibility gene was local-
ized to chromosome 13q 12—13 in 1995 [31, 32]. This gene
appears to be responsible for about 32% of hereditary
breast cancers in families with at least four breast cancer
cases in the family [20], Several other cancers appear to
be part of the BRCA2 spectrum, including pancreatic,
fallopian tube, laryngeal, uterine and male breast can-
cers as well as adult leukemia [33]. The BRCA2 gene is
composed of 27 exons distributed over roughly 70 kb of
genomic DNA, encoding a protein of 3418 amino acids.
More than 300 different mutations have been described
in the BRCA2 gene and only a few are recurrent [28],
One recurrent mutation 6174delT has a carrier frequency
of 1.5% in Jews of Eastern European descent (Ashke-
nazi) while the recurrent mutation 999del5 accounts for
a significant proportion of hereditary breast cancers in
Iceland [34, 35].
Overall, inherited germline BRCAl and BRCA2 mu-
tations occur more frequently in families with multiple
breast cancers, breast cancers along with ovarian can-
cers, both male and female breast cancers, and in indi-
Clinico-pathological features of BRCA-associated
tumors
BRCA-associated tumors have several features distinct
from sporadic breast and ovarian tumors. BRCAl-asso-
ciated tumors have a high frequency of aneuploidy and
S-phase fraction, and are typically estrogen and proges-
terone receptor negative [36, 37], Tubular and lobular
cancers are more commonly seen in BRCA2 mutation
Table 2 Criteria for referring patients for breast cancer risk assessment.
Patients should undergo genetic counseling for breast cancer suscepti-
bility if the patient's family exhibits any of the following:
• Ashkenazi Jewish ancestry11
• Male breast cancer
• Personal history of bilateral breast cancer before age 50 years
• Personal history of breast and ovarian cancer
• Strong family history of breast and ovarian cancer among
first-degree relatives
• Young age at breast or ovarian cancer onset (40-45 years)
a
 Familial breast and ovarian cancers have been studied in several
ethnic groups but are best characterized in families of Eastern Euro-
pean origin
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carriers. BRCA2-associated cancers are also more likely
to be estrogen receptor positive [38, 39]. Hedenfalk and
colleagues using DNA microarray technology have re-
cently demonstrated that significantly different groups
of genes are expressed by breast cancers with BRCA1
mutations and breast cancers with BRCA2 mutations
[40].
One study has suggested that likely BRCA mutation
carriers have higher rates of disease-free survival than
control subjects with sporadic breast cancer [41]. How-
ever, this was a retrospective study performed without
knowing the BRCA mutation status of the subjects using
definitive molecular techniques. Subsequent studies us-
ing subjects with known BRCA mutation status have
revealed that BRCA 1 -associated tumors were frequently
high grade, and these studies report worse rates of
disease-free and overall survival for BRCAJ mutation
carriers compared to non-carriers [41-43]. In a prospec-
tive cohort of 183 patients with invasive breast cancer,
treated at the Institut Curie and presenting with a
familial history of breast and/or ovarian cancer, tested
for BRCA 1 germ-line mutation, those who had a BRCA]
mutation (40 cases) had a worse outcome than those
who did not; overall survival was poorer for carriers
than for non-carriers (five-year rate, 80% vs. 91%, P -
0.002). Similar worse outcomes have also been reported
in Ashkenazi Jewish women with BRCA mutations
compared to non-carriers [43]. While the breast cancer
mortality rates of BRCA 1 carriers may be worse, it has
been observed that ovarian cancer patients with BRCA I
mutations have higher rates of disease free survival than
patients with sporadic cancer [44, 45].
Somatic TP53 mutations are often associated with
BRCA /-associated breast cancers [46]. Because tumor
cells lacking both BRCA 1/2 and p53 have unstable
genomes and are unable to repair genomic damage, these
cancers may respond better than sporadic cancers to
radiation and chemotherapeutic agents. This suggestion
is consistent with the observation that ovarian cancer
patients with BRCAJ mutations have a significantly
longer disease-free survival rate than sporadic cancer
patients, specifically after receiving Cisplatin-contain-
ing treatment following tumor reduction surgery [44].
Thus, it is unclear from the literature whether women
with BRCA mutations should be treated differently be-
cause they have a distinct form of breast cancer. Breast
and ovarian cancers are associated with greater survival
rates when they occur in younger women, so it is impos-
sible to evaluate the effects of a specific treatment on
BRCA -associated cancers per se without normalizing
for age. While BRCA -associated cancers may theo-
retically be more sensitive to therapies that promote
genomic damage, there have been no prospective
randomized studies investigating whether conventional
surgery, radiation and chemotherapeutic treatments are
more or less effective in BRCA mutation carriers than
in unselected breast and ovarian cancer patients. The
challenge for the future will be to apply our understand-
ing of the molecular functions of BRCA 1/2 to develop-
ing targeted therapies that are likely to be less toxic and
more effective.
Genetic testing to quantify breast cancer risks
While demand for genetic testing for breast cancer has
continued to rise in North America and Europe, there
are no uniform criteria for offering these tests. Rather,
the diffusion of genetic testing has largely depended on
the socio-economic status of the patient or the avail-
ability of insurance coverage. In Europe, there appears
to be a coordinated approach to provide cancer genetics
services through organized 'Cancer Family Clinics' and
in North America, the NCI has funded the Cooperative
Family Registry for Breast Cancer Studies as well as the
Cancer Genetics Network (www.cfr.epi.uci.edu). BRCA
Analysis is now available as a clinical test at a cost of
US$2,600 that is covered by most Insurance Carriers
in the US. Nonetheless, physicians are encouraged to
carefully select patients who are likely to benefit from
genetic testing and such patients must be counseled
regarding the risks, benefits and limitations of genetic
testing for adult onset cancer.
Cancer can cluster in families purely by chance or as
a result of shared environmental influences. A documen-
tation of the types of cancers in a family should be
obtained from medical records, pathology reports, and
death certificates whenever possible in an effort to con-
firm the types of cancer that have occurred in the family.
It is possible for a verbal report of cervical cancer to
later be confirmed as ovarian or endometrial cancer,
thus greatly altering the accuracy of the risk assessment.
Examples of individuals likely to benefit most from
BRCA testing and who should be offered genetic coun-
seling and testing are listed in Table 2, but genetic testing
should always be individualized and preceded by a
comprehensive cancer risk assessment. A limitation of
BRCA testing is that it does not detect all mutations in
BRCA1 and BRCA2 and it misses other genes such as
the recently localized BRCA3 gene [47].
Management of high risk women
The cumulative risk of breast cancer for women with
inherited mutations in BRCA1 or BRCA 2 could be as
low as 50% or as high as 87% by age 85 in some families
[20, 33]. Likewise, the risk of ovarian cancer has been
estimated to be anywhere from 15% to 60% by age 85 in
some BRCAl carriers [20, 33]. In a population based
study from Iceland, the penetrance for the 999del5
BRCA2 mutation was estimated to be only 37% by age
70 [35]. The extreme variations in the penetrance of
BRCAl and BRCA2 add to the complexity of genetic
counseling. While the efficacies of the different manage-
ment options are not well defined, clinicians must pro-
vide some guidance to their patients during the decision
making process. For patients who have already being
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diagnosed with a curable first primary cancer, the risks
of a second primary breast or ovarian cancer are sub-
stantial and should be factored into the management of
the first cancer. In the US, current management options
might include prophylactic surgery, intensive surveillance
and participation in chemoprevention trials as listed in
Table 3 [48-53].
Prophylactic surgery
Recent studies have shown some benefit of a prophylactic
mastectomy for select women. The strongest evidence
comes from a retrospective analysis reported by Hart-
mann and colleagues from the Mayo Clinic. The authors
studied 639 patients with family history of breast cancer
who underwent prophylactic mastectomies between
1960 and 1993 [49]. The expected number of cancers in
the patients was estimated with data from the biological
sisters of the patients (high risk group) or with use of the
Gail model (moderate risk group). In the moderate risk
group (425 women), there was an 89.5% reduction in
breast cancer incidence after prophylactic mastectomy
while in the high risk group (214 women) there was a
90% reduction. A reduction in the predicted mortality
rate was also demonstrated; the reduction was 100% for
moderate-risk patients and 93% for high risk patients. In
a recent update presented at the 91st Annual meeting of
the American Association for Cancer Research, 29 of
the 214 high risk women have been identified as BRCA1
or BRCA2 mutation carriers; none has developed breast
cancer [50]. Thus, prophylactic mastectomy undoubtedly
reduces the risk for breast cancer and remains a reason-
able option for high-risk women. However, patients
should receive extensive counseling including psycho-
logical evaluation prior to surgery since prophylactic
mastectomy is an irreversible surgical option.
Bilateral total skin sparing mastectomy may be
preferable to subcutaneous mastectomy in women who
are genetically predisposed [51, 52]. Subcutaneous mas-
tectomy removes only 90%-95% of the breast tissue,
leaving the nipple-areola complex intact and may not
be appropriate surgery for mutation carriers since any
residual breast tissue remains at risk for the development
of cancer. While there are no studies making a direct
comparison between skin sparing and subcutaneous
mastectomy, anecdotal reports suggest that women who
develop breast cancer after a mastectomy were more
likely to have been treated with subcutaneous mastec-
tomy [49]. Cosmetic outcomes after prophylactic mas-
tectomy are excellent and most women who undergo
prophylactic surgeries are satisfied with their decisions.
However, the irreversibility of the procedure and the fact
that nipple sensitivity is invariably lost makes it a less
appealing option for some women.
Bilateral oophorectomy before menopause can sub-
stantially reduce the risk of breast cancer. In BRCA1
carriers, oophorectomy has been reported to reduce
breast cancer risk (about 50%) as well as ovarian cancer
Table 3. Management options for cancer prevention in women with
BRCA mutations.
Surveillance/treatment option Frequency
Breast self-examination
Clinical breast examination
Mammography
Pelvic examination
Transvaginal ultrasound with
Color Doppler and CA 125
Prophylactic bilateral mastectomy
Prophylactic bilateral oophorectomy
Monthly beginning at age 18
Semiannually beginning at
age 25
Annually beginning at age 25
Semiannually beginning at
age 25-35
Semianually beginning at
age 25-35
Personal decision
Personal decision
Modified from Burke W, Daly M, Garber J et al. Recommendations
for follow up care of individuals with an inherited predisposition to
cancer: BRCA1 and BRCA2. JAMA 1997; 227: 997-1003.
risk (more than 80%) [53, T. R. Rebbeck personal com-
munication]. Moreover, oophorectomy has been used in
the adjuvant treatment of young women with breast
cancer. Therefore, prophylactic oophorectomy has gained
acceptance as a reasonable option for women at high risk
after childbearing is completed. It may lower the risk
of breast cancer while eliminating the risk of ovarian
cancer [54, 55]. There are however reports of peritoneal
carcinomatosis developing after prophylactic oophorec-
tomy [56]. The complications of estrogen deficiency (e.g.
osteoporosis) resulting from premature menopause after
prophylactic oophorectomy in premenopausal women
should be managed with hormone replacement therapy
and continued until they reach menopausal age (50-55
years). The protection conferred by prophylactic oopho-
rectomy does not appear to be lost after hormone
replacement therapy [53].
Intensive surveillance
For women at high risk, current screening recommen-
dations in the US include monthly breast self exams,
physician breast examinations at four to six-month in-
tervals and annual diagnostic mammograms beginning
at the age of 30 or 5-10 years earlier than the youngest
case in the family [48]. There is currently no data on the
effectiveness of this approach to reduce breast cancer
mortality in high risk women. A recent study suggested
that tumors in BRCA carriers have the same radiological
appearance as in non-carriers suggesting that yearly
screening is likely to be effective [57]. Moreover, several
studies have shown that 60%-90% of breast cancers
diagnosed in young women are evident mammographi-
cally [58]. This suggests that routine screening in high
risk women may lead to early detection and a decrease
in breast cancer mortality. However, breast density is
higher in younger women, and one small study has
suggested that increased breast density in BRCA1 car-
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riers may hamper effective mammographic screening in
these women [59]. In addition, a concern of women and
physicians is that excessive radiation exposure may be
harmful in women with BRCA mutations. Clinicians
should therefore encourage their patients to participate
in ongoing clinical trials that include the use of other
imaging technologies such as Magnetic Resonance
Imaging or Ultrasound as screening tools. However,
until the clinical trials are completed, mammographic
screening remains the only screening modality that has
been shown to reduce breast cancer mortality among
screened women and should probably be recommended.
Women with BRCA1 or BRCA2 mutations are also
at increased risk for ovarian cancer but there is no
screening test that can reliably detect ovarian cancer at
an early stage. Transvaginal ultrasound plus CA 125
every 6-12 months are frequently recommended
although there is no data to support their efficacy as
screening tools [60].
Chemoprevention of breast cancer
Results of Tamoxifen as a chemoprevention agent has
been controversial. In a recent study by the NSABP,
Tamoxifen was shown to reduce the risk of breast cancer
in high risk women from all age groups [16] but the
effectiveness of Tamoxifen in BRCA mutation carriers
has not been specifically studied. Moreover, two other
studies, also including high risk women failed to demon-
strate a reduction in risks for Tamoxifen users [61, 62].
However, a retrospective study among select women
with BRCA mutations who received adjuvant therapy
with Tamoxifen has documented a reduction in risk of
contralateral breast cancer among BRCA carriers [63].
Thus, Tamoxifen may be a reasonable breast cancer risk
reduction strategy, especially among BRCA2 mutation
carriers who generally tend to develop estrogen receptor
positive breast cancers. Oral contraceptive use has been
shown to reduce the risk of ovarian cancer in large
population based series and a similar benefit has also
been shown for BRCA carriers [64]. However, one small
study has raised the possibility that oral contraceptives
may be associated with an increased risk of breast
cancer in BRCA mutation carriers [65]. In a retrospec-
tive study by Sellers and his colleagues from the Mayo
clinic, women who have a family history of breast cancer
and who used birth control pills before 1975 were shown
to have an increased risk of breast cancer [66]. For
women at risk for both breast and ovarian cancer, the
potential benefit of 'modern' oral contraceptive pill in
reducing the risk of ovarian cancer should be weighed
against the slightly increased risk of breast cancer.
Colorectal cancer genetics
Recognition of hereditary forms of colon cancer makes
it possible to target potentially life saving preventative
interventions as well as offer the most appropriate treat-
ment for individuals with cancer. Genetic predisposition
plays a significant role in about 5%-10% of colorectal
cancer cases [67-72]. The hereditary polyposis syn-
dromes, adenomatous polyposis and hamartomatous
polyposis syndromes, make up approximately one per-
cent of the colorectal cancers diagnosed annually [67].
The hereditary non-polyposis colorectal cancer syn-
dromes, (Lynch syndromes I and II) are believed to
account for about 2%-4% of colon cancers [70]. A
variety of case-control studies have consistently shown
that a positive family history is a risk factor for colo-
rectal cancer. The lifetime risk of cancer in the sub-
groups of familial or hereditary colorectal cancer syn-
dromes varies from 15% risk in relatives of individuals
diagnosed before the age of 45 years; through 20% for
family members with two first degree relatives to ap-
proximately 70% to 95% in patients with FAP and
HNPCC [68, 70]. The American Cancer Society and
the American Gastroenterological Association recently
added a new risk category for colon cancer screening
based on the consistency of the data in numerous studies
[71, 72]. Individuals with a family history of colon cancer
are encouraged to begin screening at age 40 (rather than
age 50, as recommended for the general population).
While these recommendations have not been universally
accepted, what is more important is that physicians
recognize individuals most at risk for hereditary colo-
rectal cancer.
Familial adenomatous polyposis (FAP)
FAP is an autosomal dominant syndrome characterized
by multiple polyps (> 100) in the colon and rectum,
usually hundreds or thousands of adenomatous polyps
throughout the colon [67, 73]. The incidence is 1/8,000
but it is the most clearly defined and well understood
among the inherited colon cancer syndromes. The aver-
age age of patients at the onset of polyps is 25 years, at
the onset of symptoms (gastrointestinal bleeding, and
abdominal pain) 33 years, at diagnosis of polyposis 35
years, and at diagnosis of colon cancer, 42 years. Over
90% of cases of FAP are identified by the age of 50.
Extracolonic manifestation of FAP include multiple
mandibular osteomas, desmoid tumors, duodenal and
gastric adenomas, thyroid tumors, adrenocortical and
brain tumors and congenital hypertrophy of the retinal
pigment epithelium (CHRPE). Attenuated FAP (AFAP)
differs from the classical form in the number (usually
< 100) and localization of adenomas (proximal to the
splenic flexure) as well as age of onset which is usually
later than classical FAP (around 55 years of age) [74].
The genetic locus for FAP was mapped to chromosome
5q21—22 in 1987 and the APC (adenomatous polyposis
coli) gene was cloned in 1991 [75, 76]. The most common
mutations in the APC gene are point mutations and
microdeletions, that lead to the synthesis of a truncated
protein [77, 78].
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Genetic testing for FAP and AFAP
Both FAP and AFAP can be diagnosed by testing for
germline mutations in the A PC gene. Majority of FAP
families have protein truncating mutations in the A PC
gene and a protein truncation assay is widely used to
identify mutations [79, 80]. This method is sensitive
enough to detect about 80% of known APC mutations.
Once a mutation is known in a family, the same muta-
tion is transmitted from generation to generation in the
given kindred. Thus, testing for the APC genetic alter-
ation can be confined to the particular region of the gene
once the mutation has been identified in an index patient.
Genetic testing for APC mutations is now considered
standard of care for FAP families. This is because pre-
symptomatic genetic testing removes the necessity of
annual screening of those at-risk individuals who do not
have the gene mutation, and may increase adherence to
screening recommendations in those who have the gene
mutation.
The APCII307K missense mutation is the basis for a
form of familial CRC that has recently been described
[81, 82]. The mutation is found in 6% of the general
Ashkenazi Jewish (Eastern European) population and
explains an undefined proportion of familial CRC in
this ethnic group. Individuals with this mutation have
an increased lifetime risk of CRC with estimated odds
ratio of 1.4 to 1.9. The clinical application of this muta-
tion remains ill-defined but genetic testing for this allele
is now commercially available.
Management of patients with FAP or AFAP
Individuals who inherit a mutated APC gene have an
increased risk of developing colorectal cancer and all
primary relatives of FAP patients should be offered
screening and genetic counseling. The penetrance has
been estimated to be almost 100% [77-80]. Those at
highest risk are individuals who have a sibling, parent,
or whose children manifest the phenotype. Conventional
management of persons at increased risk for developing
FAP has been to initiate early colon surveillance by
sigmoidoscopy or colonoscopy by age 12 (Table 4). The
procedure is repeated every one to two years if polyps
are found. If polyp negative at age 12, the frequency of
colonoscopy might be reduced but many groups would
still advocate flexible sigmoidoscopies every one to two
years. Surgical therapy is the only acceptable option for
patients with FAP after colonic polyps are detected but
the timing of colectomy should be individualized based
on tthe numbers of polyps found. One study has sug-
gested that the type of mutation identified may influence
the timing of surgery but this remains controversial [78].
There is a relatively long time span from the average age
of polyp onset (age 15) to the average age of colon
cancer diagnosis in FAP (age 42). Thus, endoscopic
surveillance is the preferred management following ge-
netic testing in children. Surgery is delayed whenever
Table 4 Surveillance Protocol in FAP and HNPCC.
Genetic testing in familial colorectal cancer
Disorder
FAP
HNPCC
Lower age
limit
(years)
12
25-30
After
colectomy
20-25
30-35
30-35
30-35
Examination
Colonoscopy/sigmoidoscopy
Gastroduodenoscopy
Rectoscopy
Colonoscopy
Gynecologic examination
transvaginal ultrasound
Gastroduodenoscopy"
Abdominal ultrasound,
cytology urineb
Interval
(years)
2
1-2
1-2
1-2
1-2
1-2
1-2
a
 If gastric cancers runs in the family.
b
 If urinary tract cancers (renal pelvis, ureter) cluster in the family.
possible until the child reaches his or her 20s [79].
However, once numerous polyps are found (irrespective
of age), surveillance colonoscopy is no longer useful and
colectomy may be warranted. Rectum-sparing surgery
with sigmoidoscopic surveillance of the remaining rec-
tum is a reasonable alternative to total colectomy in
FAP patients.
Penetrance for APC mutations is nearly 100%, How-
ever in a family with a known APC mutation, if no
polyps are found in a gene carrier, colonoscopy may be
repeated every 2-3 years until the patient reaches the
age of 40. It is not indicated to surgically remove polyp-
free colons even in mutation carriers. Most patients who
have the mutated APC gene manifest colonic polyps by
age 30. Unfortunately, there is no hard core scientific
evidence for the upper bound age limits when no polyps
are found in at risk individuals. However, since colo-
rectal cancer is common in the general population, even
in the absence of polyps, these patients are encouraged
to follow American Cancer Society colon cancer sur-
veillance recommendations for the general population
after age 40 years [71]. Because of the increased risk for
polyps, upper gastrointestinal endoscopic surveillance is
usually recommended as part of research protocols.
Whether it should be routinely performed to screen for
duodenal or periampuUary cancer is controversial but
there appears to be survival advantage for individuals
who undergo surveillance and surgery for duodenal
polyposis [83].
Individuals who test negative within a family with a
known mutation have the general population risk for
colon cancer and need no additional screening. None-
theless, some programs recommend a baseline sigmoi-
doscopy by age 35 years [80].
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Polyp prevention studies
Sulindac, a nonsteroidal anti-inflammatory agent has
been shown to lead to the regression of polyps in limited
animal studies, anecdotal reports and in one random-
ized controlled clinical trial [84]. In these studies, a
decrease in the number and size of polyps was seen
before and after colectomy but the polyps were not
completely eradicated. Therefore, it is unlikely that
Sulindac will substitute for colectomy. Further clinical
studies including COX-2 inhibitors are ongoing to de-
velop new chemoprevention agents for FAP patients. As
dietary factors such as resistant starch have been shown
to have a inverse correlation with colon cancer inci-
dence, a European double blind trial is currently under
way examining the effect of Aspirin and/or resistant
starch on the prevention of appearance or progression
of polyps in FAP patients [85].
Hereditary non polyposis colon cancer (HNPCC)
Unlike FAP, patients with HNPCC do not have an
unusual number of polyps and often have a solitary
colorectal tumor. It is estimated to account for about
5% of all colon cancers [67]. HNPCC is also known as
Lynch syndrome Type I and II or Cancer Family syn-
drome. It is inherited in an autosomal dominant fashion
with variable penetrance [86-88]. HNPCC should be
suspected if there are early onset colon cancers in an
extended family, predilection to the proximal or right-
sided colon and an excess of synchronous and meta-
chronous cancers. Type II disease is distinguished from
Type I by the presence of extracolonic cancers, including
cancers originating in the uterus, ovary, ureter, renal
pelvis, stomach, pancreas, biliary tree, bone marrow,
skin, and larynx [86]. The average age at CRC diagnosis
is 44 years compared to 64 years in sporadic CRC.
Unlike sporadic cancers, which develop most often on
the left side of the colon, HNPCC cancers are most
likely to develop on the right side, defined as proximal
to the splenic flexure. In addition, mucinous and signet
cell carcinomas are common. Recently, undifferentiated
medullary or solid cribriform carcinoma has also been
described as a manifestation of CRC in HNPCC. An-
other interesting finding is the presence of tumor-infil-
trating lymphocytes as well as a Crohns disease-like
reaction and peritumoral lymphocytic infiltration [87]
which could represent an immune reaction and provide
an explanation for the known survival advantage in
HNPCC associated colon cancers.
Genetic testing for HNPCC
Criteria for genetic testing for HNPCC in the clinical
setting are not very clear. The research criteria for
HNPCC families were first established by the Interna-
tional Collaborative Group (ICG) meeting in Amster-
dam in 1990, and are known as ICG or Amsterdam
criteria [88]. These criteria are useful when reviewing a
family history and include: 1) one member diagnosed
with CRC before age 50, 2) two affected generations;
and 3) three affected relatives, one of them a first degree
relative of the other two, FAP is excluded. While these
criteria provide a general approach to identifying
HNPCC families, they are not considered to be com-
pletely inclusive. In clinical practice, the Amsterdam
criteria has been less useful because the criteria do not
take other tumor types into account and families meet-
ing this criteria only represent 0.3%—2% of CRC patients
in population based studies. In 1997, new criteria which
include adenomas as well as extracolonic HNPCC asso-
ciated tumors and histologies was proposed as a basis
for microsatellite testing candidacy in suspected HNPCC
families [89]:
1. The existence of three or more relatives with his-
tologically verified CRC, one of whom is a first-
degree relative of the other two.
2. Colorectal cancer involving at least two generations.
3. One or more cases of CRC diagnosed before the
age of 50 in the family.
4. Patients with two HNPCC-related tumors (colon,
endometrial, ovarian, ureteral cancer).
5. Patients with CRC or with first degree relative
with HNPCC-related cancer; one of the cancers
at < 45 years or adenoma < 40 years.
6. Patients with CRC or endometrial cancer < 45
years, especially if right-sided CRC or with typical
pathology.
7. Patients with adenoma < 40 years.
HNPCC is caused by mutation in one of several
DNA mismatch repair genes [100-101]. These genes
function to maintain the fidelity of DNA during replica-
tion. At least five different mismatch repair (MMR)
genes have been identified in association with HNPCC.
Genetic linkage of HNPCC was first shown to a region
on chromosome 2 in two large kindreds with HNPCC
[90]. The gene on chromosome 2 has been identified as a
DNA-mismatch-repair gene, human homolog of the
prokaryotic mutS gene, hMSH2. Other human homo-
logues of the prokaryotic DNA-mismatch-repair gene
mutL have been identified and are: MLH1 (on chromo-
some 3), PMS1 (chromosome 2q31-33), and PMS2
(chromosome 7p22) [91-93]. All these genes are mu-
tated to a variable extent in the germline of patients
with HNPCC. Recently Miyaki et al. [95] detected a
germline mutation of hMSH6 in one of five Japanese
families with HNPCC in which no mutations of
hMSH2 or hMLHl had been found. hMSH2 or
hMLHl are each mutated in about 30% of the cases
while PMSl and PMS2 are mutated in less than 5% of
the cases.
MMR deficiency gives rise to microsatellite instabil-
ities (MSI). Microsatellites are repetitive non-coding
DNA sequences of yet unknown function that are found
throughout the genome. Microsatellites can also be found
in the coding regions of genes and MMR deficiency can
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Figure I Genetic testing for HNPCC.
analysis of the tumor specimens. Even though 15% of
tumors associated with MSH2 or MLH1 mutations are
MSI-low or MSI-stable, MSI analysis is still a cost-
effective way to select families for genetic testing. It
should be noted that families with MSH6 mutations
tend to have a higher frequency of endometrial cancers
and display lower and later penetrance of colorectal
cancer. Moreover, the tumors are frequently MSI-low
or MSI-stable. A recent study reported MSH6 muta-
tions in four of 18 Dutch families with suspected
HNPCC who had MSI-low or MSI-stable tumors [98].
An algorithm for genetic testing which incorporates
MSI screening in suspected HNPCC patient is illus-
trated in Figure 1.
lead to mutations in critical genes such as APC or
KRAS that are involved in tumor initiation or progres-
sion. Molecular studies in patients with HNPCC have
shown that more than 90% of tumors have genetic
changes indicative of errors in DNA replication on
several chromosomes [96]. Therefore tumor specimens
from putative HNPCC patients can first be examined
for the presence of MSI using markers from different
chromosomal regions. Mutation analysis is often recom-
mended after tumor evaluation for MSI is positive
because tumor DNA that shows alterations in micro-
satellite regions indicate probable defects in MMR
genes. In addition, immunohistochemistry using anti-
bodies directed at the different proteins could be helpful
in deciding which particular gene to screen for. As an
example, a patient with high MSI and lack of MLH1
protein expression in the tumor is likely to harbor a
germline mutation in the MLH1 gene. Thus,a protein
truncation assay for the MMR gene hMLHl is then
performed on RNA extracted from a blood sample of
the patient. The nature of the truncating mutation is
determined by sequencing and screening for the specific
mutation could then be offered to at risk family mem-
bers. Genetic testing for HNPCC is limited by the fact
that existing tests fail to detect mutations in as many as
20%-30% of individuals who have the typical form of
HNPCC. The current sensitivity for genetic testing is
only 50%-95% depending on the methodology used.
Screening for mutations in MMR genes is both time
consuming and expensive, given the heterogeniety in the
spectrum of mutations in all five genes. Thus, MSI
screening has been evaluated as a cost-effective way to
select patients for testing by Aaltonen and colleagues in
a population based series of 509 colorectal cancer cases
from Finland [97]. Sixty-three tumors (12%) showed
MSI, and 10 of these patients had a germline mutation
in MSH2 or MLHl. Nine of the mutation carriers had
a first degree relative with colorectal cancer or endo-
metrial cancer, seven were younger than 50 years, and
four had a colorectal or endometrial cancer previously.
Similar findings have been reported by other groups,
hence the current recommendation to begin testing with
MSI analysis combined with immunohistochemical
Management of HNPCC
To provide optimal care for HNPCC families, a multi-
disciplinary approach is recommended because of the
complexities involved in identifying at risk individuals,
interpreting test results and discussing the clinical im-
plications of a positive test. A multidisciplinary expert
panel recently provided specific recommendations for
screening and surveillance of individuals with an average
or elevated risk of colorectal cancer (Table 4) [99-101].
Patients with a history suggestive of HNPCC should
receive genetic counseling and be screened for muta-
tions in MMR genes. Individuals who test positive for a
deleterious mutation should have a colonoscopy every
1 to 2 years starting between the age of 20 and 25 years
and every year after age 40 years. Patients with HNPCC
with curable colorectal cancer should have a subtotal
colectomy because synchronous or metachronous colon
cancers occur in 35% of patients. Because the risk of
developing rectal cancer is approximately 12% in the
first 12 years after subtotal colectomy the rectum should
be examined annually by sigmoidoscopy [99].
While the lifetime risk for colorectal cancer is 70%
to 85% for hMLHl and hMSH2 mutation carriers,
prophylactic subtotal colectomy is usually not recom-
mended because of the increased risk for other cancers
e.g. endometrial cancer (50% lifetime risk) and other
extracolonic cancers (about 15% lifetime risk) [100-102].
Female HNPCC mutation carriers have increased risk
of endometrial cancer as well as ovarian cancer, there-
fore, endometrial and ovarian cancer screening may be
warranted (Table 4). Unfortunately, there is no effective
way to prevent cancer in mutation carriers. In addition,
for families with urinary tract cancers, screening with
abdominal ultrasound and urine cytology may be war-
ranted.
Importance of a coordinated multidisciplinary
approach to cancer genetic counseling
Genetic testing for adult-onset disorders raises numerous
ethical, legal, and social concerns such as adverse psy-
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chological consequences for the individual and his/her
family, loss of insurance or employment, and social
stigmatization [1-4]. Informed consent must be given in
accordance with published guidelines on genetic testing
[1-4]. In order to give informed consent a patient must
understand the advantages, disadvantages, risks, limita-
tions and consequences of genetic tests. The impact of
genetic testing on an individual depends on their per-
ceived risk of cancer, personal experiences with cancer,
understanding of cancer, self-image, and social and
family relationships. All these factors should be eval-
uated before genetic testing. Recent studies have shown
that the uptake of genetic testing in families with
HNPCC varied widely, from 43% in the US to 75% in
Finland [104]. One reason for the differences might
be related to differences in the health care and social
security systems in the US and Europe. In breast cancer
families, test uptake correlates with socioeconomic
status and the educational background of the women
[105, 106]. One feature that seems to be common to
breast cancer family clinics in several countries is a
strong bias towards higher social class among indi-
viduals seeking genetic testing [106]. More work is
needed to examine the special needs of low social class
individuals and ethnic minorities.
Genetic testing may have adverse psychological con-
sequences and social risks and it should be undertaken
in multiple steps. The likelihood of adverse psycholog-
ical response to genetic testing must be evaluated during
the pre-test counseling process and before blood is drawn
for testing. To date, most studies have failed to docu-
ment serious adverse effects in individuals who choose to
know their mutation status [104, 106-108]. Most signifi-
cantly, one study has concluded that individuals with
strong family histories of breast and ovarian cancer
experience higher levels of cancer-related stress and
depression by choosing not to participate in an educa-
tional session to learn their mutation status [106]. Darval
et al., in a recent study, assessed the ability of individuals
who undergo genetic testing for cancer susceptibility to
accurately anticipate emotional reactions to disclosure
of their test results [108]. They found that in general,
patients that did not have a personal history of cancer
were fairly accurate in predicting their responses to test
results. Interestingly, cancer patients tended to under-
estimate their reactions to receiving their test results and
experienced more distress than anticipated. These data
underscore the importance of providing adequate pre
and post test counseling for patients who are contem-
plating genetic testing. Resources for psychological
counseling should be readily available to individuals
who are identified as high risk.
Prophylactic surgery remains a viable option for
BRCA mutation carriers but such women should have
consultation with surgeons (breast and reconstructive
surgery) and be extensively counseled about the poten-
tial outcomes prior to surgery. A recent study completed
in the Netherlands demonstrated that 48% of young
women included in the study who were at 50% risk to
have a BRCA mutation requested DNA testing; 51% of
these women who were eligible for prophylactic surgery,
decided on prophylactic mastectomy and 64% opted for
oophorectomy. Additionally, the authors found that age,
having children, and high pre-test risk were positively
associated with the decisions to undergo testing and
prophylactic surgery [109]. In another study from Aus-
tralian, the intention to undergo prophylactic mastec-
tomy after receiving a positive mutation result was
found to directly correlate with a woman's degree of
breast cancer anxiety [110]. It is therefore important for
health care providers to incorporate the psychosocial
aspects of genetic testing and cancer screening in their
management of high risk families.
The complexities of genetic counseling for cancer make
it time consuming and not compatible with general or
mainline oncology practice. Hence, many academic cen-
ters in the US and in Europe have developed specialized
programs in clinical cancer genetics that are multi-
disciplinary in approach and involve the participation
of genetic counselors, nurse specialists, social workers,
psychologists, surgeons/gynecologists, radiologists and
physicians with expertise in cancer genetics. It is no
longer sufficient to refer patients to established medical
genetics clinics where there is no provision for a coordi-
nated mechanism for follow up of the patients e.g.
ensuring that high risk women get annual mammography
and other cancer screening tests. Therefore, oncologists
are encouraged to embrace the concept of cancer family
clinics that serve multiple purposes including ascertain-
ment of cases, risk assessment, genetic counseling and
testing, coordination of longitudinal follow up and re-
sponding to the psychosocial needs of family members.
As genetic testing for common cancers such as breast, or
colon become standard of care, oncologists are encour-
aged to assume the responsibility of coordinating the care
of their patients and their at risk family members.
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